Download anti-depressants

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Discovery and development of dipeptidyl peptidase-4 inhibitors wikipedia , lookup

5-HT3 antagonist wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Prescription costs wikipedia , lookup

Discovery and development of direct thrombin inhibitors wikipedia , lookup

Medication wikipedia , lookup

Pharmacognosy wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Discovery and development of direct Xa inhibitors wikipedia , lookup

Discovery and development of cyclooxygenase 2 inhibitors wikipedia , lookup

Discovery and development of neuraminidase inhibitors wikipedia , lookup

Drug interaction wikipedia , lookup

Bilastine wikipedia , lookup

Discovery and development of integrase inhibitors wikipedia , lookup

Stimulant wikipedia , lookup

Metalloprotease inhibitor wikipedia , lookup

Discovery and development of ACE inhibitors wikipedia , lookup

Serotonin wikipedia , lookup

Fluoxetine wikipedia , lookup

Serotonin syndrome wikipedia , lookup

Neuropharmacology wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Psychopharmacology wikipedia , lookup

Transcript
ANTI-DEPRESSANTS
Depression is a serious disorder that afflicts in adults throughout the world. Anti
depressions are used to treat the depression.
Symptoms of depression: Hopelessness, feelings of sadness, and despair, loss of energy,
changes in sleep patterns, appetite, and suicidal thoughts.
Mechanism of action of antidepressants: According to the monoamine hypothesis of
depression postulates a deficiency in serotonin or nor-epinephrine neurotransmission in the brain.
Most of the currently used antidepressants work by slowing the removal of both nor-epinephrine
and serotonin from the brain, thus increasing the availability of these neurotransmitters. As a
result, they are efficacious for patients whose depression is caused by the imbalance of either
nor-epinephrine or serotonin.
Drug therapy for antidepressants:
1. TCAs (Tri-cyclic antidepressants): Amitriptyline, Clomipramine, Desipramine,
Doxepin, Dothiepin, Imipramine, Melitracen, Nortriptyline, Trimipramine.
2. Tetracyclic antidepressants: Mianserin, Maprotiline.
3. SSRIs (Selective Serotonin Reuptake Inhibitors): Fluoxetine, Paroxetine, Sertraline,
Fluvoxamine, Citalopram, Escitalopram.
4. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Venlafaxine/ Venlafaxine
XR, Duloxetine.
5. Atypical antidepressants: Mirtazapine.
6. MAOIs (Monoamine Oxidase Inhibitors): Moclobemide, Phenelzine, Isocarboxazid,
Tranylcypromine.
7. Lithium salts: Lithium carbonate.
Tri-cyclic Antidepressants: The TCAs (tri-cyclic antidepressants) blocks serotonin and norepinephrine reuptake into the neuron. The TCAs include the tertiary amines amitriptyline,
clomipramine, doxepin, imipramine, and trimipramine and the secondary amines include
desipramine, nor-triptyline and protriptyline. All the drugs have similar therapeutic efficacy and
the choice of drugs depend upon patient prior response, tolerance, preexisting medical
conditions, and duration of action.
Mechanism of action:

Blocking of receptors: Amoxapine also blocks the D2 receptor.TCAs also block
adrenergic, histaminic, serotonergic, and muscarinic receptors.

Inhibition of neurotransmitter reuptake: TCAs and amoxapine are potent inhibitors of the
neuronal reuptake of nor-epinephrine and serotonin into presynaptic nerve terminals. The
TCAs cause increased concentrations of monoamines in the synaptic cleft, ultimately
resulting in antidepressant effects, by blocking the major route of neurotransmitter
removal. At therapeutic concentrations, TCA does not block dopamine transporters.
Desipramine and maprotiline are the selective inhibitors of nor-epinephrine reuptake.
Pharmacokinetics: These are well absorbed upon orally, widely distributed and readily
penetrate into the CNS. These drugs are metabolized by the hepatic microsomal system and
excreted as inactive metabolites via the kidney.
Side effects: Dizziness, blurred vision, constipation, dry mouth, headache, sweating, tremor,
palpitation, difficulty passing urine, liver dysfunction, orthostatic hypotension, seizure, ECG
changes and abnormal blood count.
Therapeutic uses: Cardiac arrhythmias and other serious cardiovascular problems, effective in
treating moderate to severe major depression, used to treat migraine headache and chronic pain
syndromes.
Mianserin: It was originally designed as an anti-allergic drug, subsequently, a variety of clinical
trials have indicated that Mianserin possesses antidepressant activity equal to that of the widely
used tri-cyclic antidepressants. It is a tetra-cyclic compound structurally distinct from both the
classical tri-cyclic antidepressants and from bridged tri-cyclic of the maprotiline type.
Selective Serotonin Reuptake Inhibitors: The selective serotonin reuptake inhibitors (SSRIs)
are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin
reuptake, having 300- to 3000-fold greater selectivity for the serotonin transporter as compared
to the nor-epinephrine transporter. SSRIs include citalopram, escitalopram, fluoxetine,
fluvoxamine, paroxetine, and sertraline. Escitalopram is the pure S-enatiomer of citalopram.
Both citalopram and fluoxetine are racemic mixtures, of which the respective S-enantiomers are
the more potent inhibitors of the serotonin reuptake pump. The SSRIs block the reuptake of
serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and,
ultimately, to greater postsynaptic neuronal activity.
Pharmacokinetics: Food has little effect on absorption. All of the SSRIs are well absorbed after
oral administration. Peak levels are seen in approximately 2- 8 hours on average.
Side effects: Anxiety, dry mouth, headache, nausea, vomiting, gastrointestinal discomfort,
somnolence, tremor, sweating, sexual dysfunction and weight loss, etc. Occasionally, some
patients may experience insomnia, excitement, restlessness or seizure.
Therapeutic uses: Used to treat psychiatric disorders, posttraumatic stress disorder, panic
disorder, generalized anxiety disorder, social anxiety disorder, and bulimia nervosa.
Serotonin-Nor-epinephrine Reuptake Inhibitors: These agents, termed selective serotoninnor-epinephrine reuptake inhibitors (SNRIs), may be effective in treating depression in patients
in whom SSRIs are ineffective.
Venlafaxine: It is a potent inhibitor of serotonin reuptake and, at medium to higher doses, is an
inhibitor of nor-epinephrine re-uptake. It is also a mild inhibitor of dopamine reuptake at high
doses. Venlafaxine has minimal inhibition of the cytochrome P450 isoenzymes and is a substrate
of the CYP2D6 isoenzyme.
Side effects: Headache, nausea, dizziness, sexual dysfunction, insomnia, sedation, and
constipation. At high doses, increase in blood pressure and heart rate.
Duloxetine: It inhibits the serotonin and nor-epinephrine reuptake at all doses. It is extensively
metabolized in the liver to numerous metabolites. Metabolites are excreted in the urine, and the
use of duloxetine is not recommended in patients with end-stage renal disease and it should not
be administered to patients with hepatic insufficiency.
Side effects: Constipation, dry mouth, nausea, diarrhea, sexual dysfunction and weight loss,
vomiting, insomnia, dizziness, somnolence, and sweating are also seen. These drugs may cause
hypertension at high doses.
Mirtazapine: This drug enhances nor-epinephrine and serotonin neurotransmission via
mechanisms related to its ability to block presynaptic receptors. Mirtazapine is markedly
sedating, which may be used to advantage in depressed patients having difficulty sleeping.
Monoamine Oxidase Inhibitors: MAO is a mitochondrial enzyme found in nerve and other
tissues, such as the liver and gut. The MAO inhibitors may reversibly or irreversibly inactivate
the enzyme, permitting neurotransmitter molecules to escape degradation and, therefore, to both
accumulate within the presynaptic neuron and leak into the synaptic space. 3 MAO inhibitors are
currently available for treatment of depression: selegiline, which is the first antidepressant
available in a transdermal delivery system, phenelzine and tranylcypromine, the agent that was
prior-approved for Parkinson's disease, but is now also approved for depression.
Mechanism of action: These drugs inhibit not only MAO in the brain but also MAO in the liver
and gut that catalyze oxidative deamination of drugs and potentially toxic substances, such as
tyramine, which is found in certain foods. Most MAO inhibitors, such as phenelzine, form stable
complexes with the enzyme, causing irreversible inactivation. This results in increased stores of
serotonin, nor-epinephrine, and dopamine within the neuron and subsequent diffusion of excess
neurotransmitter into the synaptic space.
Pharmacokinetics: These drugs are well absorbed orally, metabolized and excreted rapidly in
the urine.
Side effects: Dizziness, headache, nervousness, gastrointestinal disturbance, sweating, vomiting
and hypertensive crisis.
Therapeutic uses: Useful in the treatment of phobic states, atypical depression.
Lithium carbonate: This medication is used to treat manic-depressive disorder (bipolar
disorder). It works to stabilize the mood and reduce extremes in behavior by restoring the
balance of certain natural substances (neurotransmitters) in the brain.
Side effects of Lithium salts: Bitter taste, dry mouth, tremor, polyuria, fatigue and weight gain.
Other less-common side effects include hyperthyroidism, hypothyroidism, ECG changes, raised
anti-diuretic hormone concentrations, renal failure or leucocytosis.